News

AstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backing
The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...
BioPharma Dive1d
AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial
The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...
AstraZeneca’s Anselamimab Misses Primary Endpoint in Amyloidosis Trials, Shows Promise in Subgroup
Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...
AstraZeneca's rare immune disorder drug succeeds in advanced trial
AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...
Construction Dive2d
AstraZeneca grows US presence with $50B in spending plans
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...
GEN - Genetic Engineering and Biotechnology News21h
Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs
This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.
Explore more
The Progress-Index3d
Mayor confirms Petersburg is courting AstraZeneca to build billion-dollar facility here
On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...
InsideNoVa on MSN3d
AstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobs
In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...
AstraZeneca Expected to Post Higher Core EPS, Total Revenue -- Earnings Preview
AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.
AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation
"attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to ...